Communiqués Cumberland Pharmaceuticals Inc.

Actions

CPIX

US2307701092

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/08/2026			Varia. 5j.	Varia. 1 janv.
7,800 ^USD	+1,56%		+16,77%	+95,98%

04/08	Cumberland Pharmaceuticals Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
04/08	Transcript : Cumberland Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 04, 2026

Communiqués

04/08	Cumberland: Q2 Earnings Snapshot	AQ
04/08	CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS	PR
28/07	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS	PR
13/07	Cumberland Pharmaceuticals : C O R R E C T I O N Cumberland Pharmaceuticals Inc./	PU
13/07	/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./	PR
01/07	Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex	PR
26/06	Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference	PR
19/06	RedHill Biopharma Announces Up To $19.4 Million Private Placement	AQ
03/06	RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms	AQ
02/06	Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis	PR
28/05	CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA	PR
05/05	Cumberland: Q1 Earnings Snapshot	AQ
05/05	CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE	PR
28/04	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE	PR
23/04	Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex	PR
22/04	RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026	PR
16/04	CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE	PR
18/03	Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting	AQ
17/03	Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting	PR
09/03	Cumberland Pharmaceuticals : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU
03/03	Cumberland: Q4 Earnings Snapshot	AQ
03/03	CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH	PR
25/02	Joint U.S. Commercialization of RedHill's Talicia® Commences	PR
25/02	CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®	PR
24/02	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE	PR